Literature DB >> 20931245

Comparative EEG mapping studies in Huntington's disease patients and controls.

Annamaria Painold1, Peter Anderer, Anna K Holl, Martin Letmaier, Gerda M Saletu-Zyhlarz, Bernd Saletu, Raphael M Bonelli.   

Abstract

Huntington's disease (HD) is a devastating neurodegenerative disorder with prominent motor and cognitive decline. Previous studies with small sample sizes and methodological limitations have described abnormal electroencephalograms (EEG) in this cohort. The aim of the present study was to investigate objectively and quantitatively the neurophysiological basis of the disease in HD patients as compared to normal controls, utilizing EEG mapping. In 55 HD patients and 55 healthy controls, a 3-min vigilance-controlled EEG (V-EEG) was recorded during midmorning hours. Evaluation of 36 EEG variables was carried out by spectral analysis and visualized by EEG mapping techniques. To elucidate drug interference, the analysis was performed for the total group, unmedicated patients only and between treated and untreated patients. Statistical overall analysis by the omnibus significance test demonstrated significant (p < 0.01 and p < 0.05) EEG differences between HD patients and controls. Subsequent univariate analysis revealed a general decrease in total power and absolute alpha and beta power, an increase in delta/theta power, and a slowing of the centroids of delta/theta, beta and total power. The slowing of the EEG in HD reflects a disturbed brain function in the sense of a vigilance decrement, electrophysiologically characterized by inhibited cortical areas (increased delta/theta power) and a lack of normal routine and excitatory activity (decreased alpha and beta power). The results are similar to those found in other dementing disorders. Medication did not affect the overall interpretation of the quantitative EEG analysis, but certain differences might be due to drug interaction, predominantly with antipsychotics. Spearman rank correlations revealed significant correlations between EEG mapping and cognitive and motor impairment in HD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931245     DOI: 10.1007/s00702-010-0491-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  45 in total

1.  Quantitative EEG findings in different stages of Alzheimer's disease.

Authors:  Yong Tae Kwak
Journal:  J Clin Neurophysiol       Date:  2006-10       Impact factor: 2.177

2.  Topographic classification of EEG patterns in Huntington's disease.

Authors:  R Bellotti; F De Carlo; R Massafra; M de Tommaso; V Sciruicchio
Journal:  Neurol Clin Neurophysiol       Date:  2004-11-30

3.  Attention deficits in Alzheimer's disease and vascular dementia.

Authors:  Bernadette McGuinness; Suzanne L Barrett; David Craig; John Lawson; A Peter Passmore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-02       Impact factor: 10.154

4.  Transformations towards the normal distribution of broad band spectral parameters of the EEG.

Authors:  T Gasser; P Bächer; J Möcks
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1982-01

5.  Computer analysis of EEG activity in dementia of the Alzheimer's type and Huntington's disease.

Authors:  L J Streletz; P F Reyes; M Zalewska; L Katz; R G Fariello
Journal:  Neurobiol Aging       Date:  1990 Jan-Feb       Impact factor: 4.673

6.  Sources of cortical rhythms in adults during physiological aging: a multicentric EEG study.

Authors:  Claudio Babiloni; Giuliano Binetti; Andrea Cassarino; Gloria Dal Forno; Claudio Del Percio; Florinda Ferreri; Raffaele Ferri; Giovanni Frisoni; Silvana Galderisi; Koichi Hirata; Bartolo Lanuzza; Carlo Miniussi; Armida Mucci; Flavio Nobili; Guido Rodriguez; Gian Luca Romani; Paolo M Rossini
Journal:  Hum Brain Mapp       Date:  2006-02       Impact factor: 5.038

7.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 8.  Thalamic mechanisms of EEG alpha rhythms and their pathological implications.

Authors:  Stuart W Hughes; Vincenzo Crunelli
Journal:  Neuroscientist       Date:  2005-08       Impact factor: 7.519

9.  Quantitative EEG and dynamic susceptibility contrast MRI in Alzheimer's disease: a correlative study.

Authors:  Donatella Mattia; Fabio Babiloni; Andrea Romigi; Febo Cincotti; Luigi Bianchi; Francesca Sperli; Fabio Placidi; Alessandro Bozzao; Patrizia Giacomini; Roberto Floris; Maria Grazia Marciani
Journal:  Clin Neurophysiol       Date:  2003-07       Impact factor: 3.708

10.  Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study.

Authors:  Claudio Babiloni; Giuliano Binetti; Emanuele Cassetta; Gloria Dal Forno; Claudio Del Percio; Florinda Ferreri; Raffaele Ferri; Giovanni Frisoni; Koichi Hirata; Bartolo Lanuzza; Carlo Miniussi; Davide V Moretti; Flavio Nobili; Guido Rodriguez; Gian Luca Romani; Serenella Salinari; Paolo M Rossini
Journal:  Clin Neurophysiol       Date:  2005-12-27       Impact factor: 3.708

View more
  11 in total

1.  Arousal and the control of perception and movement.

Authors:  E Garcia-Rill; T Virmani; J R Hyde; S D'Onofrio; S Mahaffey
Journal:  Curr Trends Neurol       Date:  2016

2.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

3.  EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease.

Authors:  Annamaria Painold; Peter Anderer; Anna K Holl; Martin Letmaier; Gerda M Saletu-Zyhlarz; Bernd Saletu; Raphael M Bonelli
Journal:  J Neurol       Date:  2010-12-12       Impact factor: 4.849

4.  Changes in brain activity with tominersen in early-manifest Huntington's disease.

Authors:  D J Hawellek; P Garces; A H Meghdadi; S Waninger; A Smith; M Manchester; S A Schobel; J F Hipp
Journal:  Brain Commun       Date:  2022-06-09

5.  Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.

Authors:  Simon P Fisher; Michael D Schwartz; Sarah Wurts-Black; Alexia M Thomas; Tsui-Ming Chen; Michael A Miller; Jeremiah B Palmerston; Thomas S Kilduff; Stephen R Morairty
Journal:  Sleep       Date:  2016-02-01       Impact factor: 5.849

6.  Walking-Related Dual-Task Interference in Early-to-Middle-Stage Huntington's Disease: An Auditory Event Related Potential Study.

Authors:  Marina de Tommaso; Katia Ricci; Anna Montemurno; Eleonora Vecchio; Sara Invitto
Journal:  Front Psychol       Date:  2017-07-31

Review 7.  Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?

Authors:  Michael K Leuchter; Elissa J Donzis; Carlos Cepeda; Aimee M Hunter; Ana María Estrada-Sánchez; Ian A Cook; Michael S Levine; Andrew F Leuchter
Journal:  Front Neurol       Date:  2017-03-30       Impact factor: 4.003

8.  EEG may serve as a biomarker in Huntington's disease using machine learning automatic classification.

Authors:  Omar F F Odish; Kristinn Johnsen; Paul van Someren; Raymund A C Roos; J Gert van Dijk
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

9.  Early impairment of thalamocortical circuit activity and coherence in a mouse model of Huntington's disease.

Authors:  Justin L Shobe; Elissa J Donzis; Kwang Lee; Samiksha Chopra; Sotiris C Masmanidis; Carlos Cepeda; Michael S Levine
Journal:  Neurobiol Dis       Date:  2021-07-16       Impact factor: 5.996

10.  Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Szilvia Vas; Jackie M Casey; Will T Schneider; Lajos Kalmar; A Jennifer Morton
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.